Joseph Weber, MD
Pulmonary Disease · West Allis, WINPI 1881870277
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,045 of the $9,797 with a category attached, or 71.9%. Intuitive Surgical accounts for 83.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $8,357, more than ten times the $566 reported in 2019.
Across 41 payments — averaging $238.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$930
- GSK$150
- Genentech USA, Inc.$131
- Procept Biorobotics Corporation$128
- Sunovion Pharmaceuticals Inc.$63
- plus $207 from 7 others
What the payments were for
- Speaking & faculty fees$7508%
- Travel & lodging$1,17912%
- Food & beverage$8238%
- Education$7,04572%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $8,188 |
| AstraZeneca | 6 | $930 |
| GSK | 5 | $150 |
| Genentech USA, Inc. | 1 | $131 |
| Procept Biorobotics Corporation | 1 | $128 |
| Sunovion Pharmaceuticals Inc. | 6 | $63 |
| Insmed, Inc. | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $42 |
| Philips North America LLC | 2 | $40 |
| Novartis | 2 | $27 |
| Astellas Pharma US Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Biogen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,149
- FASENRA$854
- AquaBeam Robotic System$128
- NUCALA$117
How this compares
$9,797 in reported general payments places this provider in the 85th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 37 | $548,229 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 652 | $538,225 |
| XolairOmalizumab | 40 | $142,590 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 185 | $98,974 |
| Breo ElliptaFluticasone/Vilanterol | 159 | $88,983 |
| Dupixent PenDupilumab | 17 | $71,278 |
| Spiriva RespimatTiotropium Bromide | 90 | $65,276 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $53,373 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 80 | $47,022 |
| SymbicortBudesonide/Formoterol Fumarate | 114 | $32,430 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 149 | $22,170 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 34 | $20,914 |
| Advair HfaFluticasone Propion/Salmeterol | 34 | $20,648 |
| Spiriva HandihalerTiotropium Bromide | 24 | $19,868 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 584 | $15,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $150 | $754,4891,079 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $15 | $681,442241 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Daliresp | $930 | $99,625209 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in West Allis
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.